Can a 'Universal' cancer target outsmart resistant blood cancers?
NCT ID NCT07749976
First seen Aug 06, 2026 · Last updated Aug 07, 2026 · Updated 1 time
Summary
This early-phase trial is testing an experimental drug called VTRU200 in people with certain blood cancers that have returned or not responded to standard treatments, including acute myeloid leukemia, high-risk myelodysplastic syndromes, and diffuse large B-cell lymphoma after CAR-T therapy. VTRU200 is designed to help the immune system's T cells recognize and attack cancer cells by binding to stress signals common on many cancer types, rather than a single protein. The study aims to find a safe dose, understand how the drug behaves in the body, and look for early signs that it can shrink or control the cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- VTRU200, an investigational trispecific T-cell engager given by intravenous infusion
- What this could lead to
- If VTRU200 proves safe and shows early signs of activity, it could become a new treatment option for people with blood cancers that have stopped responding to other therapies.
- What could go wrong
- This is a first-in-human trial, so the safety and effectiveness of VTRU200 are unknown. It may not work as hoped, and side effects could be significant. The trial is early-stage and small, so results may not apply to a larger population.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill keep blood cancer at bay after a stem cell transplant?
- Could muscle loss predict blood cancer outcomes?
- Can a modified enzyme starve Hard-to-Treat blood cancers?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Talking about the end: could guided conversations reduce futile cancer treatments?